id: NEW:lean_nafld_to_liver_disease_mortality
name: Nonalcoholic Fatty Liver Disease in Lean Individuals â†’ Liver Disease Mortality
from_node:
  node_id: NEW:lean_nafld
  node_name: Nonalcoholic Fatty Liver Disease in Lean Individuals
to_node:
  node_id: liver_disease_mortality
  node_name: Liver Disease Mortality
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Lean individuals develop NAFLD through metabolic dysfunction (insulin resistance,
  dyslipidemia) despite normal body weight, with genetic variants (PNPLA3, TM6SF2)
  potentially contributing to susceptibility'
- 'Step 2: Hepatic steatosis progresses to nonalcoholic steatohepatitis (NASH) in
  up to 1 in 4 individuals with NAFLD, involving hepatocyte injury, inflammation,
  and oxidative stress'
- 'Step 3: Persistent hepatic inflammation and injury drive progressive fibrosis through
  activation of hepatic stellate cells and extracellular matrix deposition'
- 'Step 4: Advanced fibrosis progresses to cirrhosis with portal hypertension, synthetic
  dysfunction, and risk of hepatic decompensation'
- 'Step 5: Cirrhotic liver disease leads to complications including variceal bleeding,
  ascites, hepatic encephalopathy, and hepatocellular carcinoma, ultimately increasing
  liver-related mortality'
evidence:
  quality_rating: B
  n_studies: 4
  primary_citation: 'M. Long et al. 2022. AGA Clinical Practice Update: Diagnosis
    and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert
    Review. Gastroenterology.'
  supporting_citations: []
description: Lean NAFLD (affecting 7-20% of all NAFLD cases) is associated with increased
  liver-related mortality through progression to NASH, cirrhosis, hepatic decompensation,
  and hepatocellular carcinoma. Multiple studies demonstrate that lean individuals
  with NAFLD have increased liver mortality relative to those without NAFLD, highlighting
  that normal body weight does not confer protection against severe liver outcomes.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
moderators:
- name: fibrosis_stage
  direction: strengthens
  strength: strong
  description: Advanced fibrosis (F3-F4) substantially increases liver-related mortality
    risk compared to early-stage disease
- name: presence_of_NASH
  direction: strengthens
  strength: strong
  description: Progression from simple steatosis to NASH significantly increases risk
    of fibrosis progression and liver-related mortality
- name: type_2_diabetes_mellitus
  direction: strengthens
  strength: moderate
  description: Comorbid T2DM accelerates disease progression and increases mortality
    risk
- name: genetic_variants
  direction: strengthens
  strength: moderate
  description: PNPLA3 and TM6SF2 variants may increase susceptibility to disease progression
